United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.59 USD
-5.15 (-1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $331.56 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 21 - 40 ( 598 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4/FY23: Rounding Out the Year of Tyvaso DPI w/ Another Record Revenue Quarter
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Near-Term Growth With TETON Program Broadening Upside; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2024 Outlook on Covered Companies Takeaways from Annual SF Biotech Meetings
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Federal Circuit Affirms ''793 PTAB Decision; Tyvaso DPI''s Dominance to Persist
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Optimized Entry and Exit Levels for UTHR 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Defines Near-Term Growth With TETON Program As Next Chapter; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Record Quarterly Revenue Led by Tyvaso Franchise; Organ Manufacturing Updates
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department